433 related articles for article (PubMed ID: 23649935)
21. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
[TBL] [Abstract][Full Text] [Related]
22. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
23. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
[TBL] [Abstract][Full Text] [Related]
24. Comparability study of Rituximab originator and follow-on biopharmaceutical.
Montacir O; Montacir H; Eravci M; Springer A; Hinderlich S; Saadati A; Parr MK
J Pharm Biomed Anal; 2017 Jun; 140():239-251. PubMed ID: 28371718
[TBL] [Abstract][Full Text] [Related]
25. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
26. Heterologous recombinant expression of non-originator NISTmAb.
Kashi L; Yandrofski K; Preston RJ; Arbogast LW; Giddens JP; Marino JP; Schiel JE; Kelman Z
MAbs; 2018; 10(6):922-933. PubMed ID: 29958062
[TBL] [Abstract][Full Text] [Related]
27. Cation exchange chromatography on a monodisperse 3 µm particle enables extensive analytical similarity assessment of biosimilars.
Füssl F; Millán-Martín S; Bones J; Carillo S
J Pharm Biomed Anal; 2023 Sep; 234():115534. PubMed ID: 37343453
[TBL] [Abstract][Full Text] [Related]
28. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice.
Avouac J; Cougnaud Murail R; Goulvestre C; Dumas S; Molto A; Miceli-Richard C; Conort O; Batteux F; Allanore Y
Semin Arthritis Rheum; 2022 Feb; 52():151951. PubMed ID: 35038642
[TBL] [Abstract][Full Text] [Related]
30. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
[TBL] [Abstract][Full Text] [Related]
31. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.
Jurczak W; Moreira I; Kanakasetty GB; Munhoz E; Echeveste MA; Giri P; Castro N; Pereira J; Akria L; Alexeev S; Osmanov E; Zhu P; Alexandrova S; Zubel A; Harlin O; Amersdorffer J
Lancet Haematol; 2017 Aug; 4(8):e350-e361. PubMed ID: 28712941
[TBL] [Abstract][Full Text] [Related]
32. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
[TBL] [Abstract][Full Text] [Related]
33. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.
Xie H; Chakraborty A; Ahn J; Yu YQ; Dakshinamoorthy DP; Gilar M; Chen W; Skilton SJ; Mazzeo JR
MAbs; 2010; 2(4):379-94. PubMed ID: 20458189
[TBL] [Abstract][Full Text] [Related]
34. Rapid identification of an antibody DNA construct rearrangement sequence variant by mass spectrometry.
Scott RA; Rogers R; Balland A; Brady LJ
MAbs; 2014; 6(6):1453-63. PubMed ID: 25484040
[TBL] [Abstract][Full Text] [Related]
35. Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar.
Fazel R; Mahboudi F; Seyedjafari E; Sardari S; Vaziri B
Iran J Biotechnol; 2019 Dec; 17(4):e2470. PubMed ID: 32671128
[TBL] [Abstract][Full Text] [Related]
36. Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.
Miao S; Fan L; Zhao L; Ding D; Liu X; Wang H; Tan WS
Biomed Res Int; 2017; 2017():4926168. PubMed ID: 28349061
[TBL] [Abstract][Full Text] [Related]
37. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
[TBL] [Abstract][Full Text] [Related]
38. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
[TBL] [Abstract][Full Text] [Related]
39. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Structural, Biological, and Functional Similarity of Biosimilar Granulocyte Colony Stimulating Factor to its Reference Product.
Bor Tekdemir Z; Seckin AI; Kacar T; Yilmaz E; Bekiroglu S
Pharm Res; 2020 Oct; 37(11):215. PubMed ID: 33026512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
